Eli Lilly accelerates drug development using AI and natural language processing
The Client
Eli Lilly is a pharmaceutical company that discovers, develops, manufactures, and sells products. With offices in 18 countries, Eli Lilly’s products are sold in approximately 125 countries.
The Objective
Eli Lilly’s goal is to develop new and better medicines and solutions for patients with high efficiency and speed, based on insights generated from high-quality data.
The Solution
Leveraging our connections and expertise, our team mapped out the relevant technology landscape. Through our guided process, Eli Lilly selected artificial intelligence startup Coseer to help them achieve their goal.
The Outcome
A pilot to validate Coseer’s ability to expedite the document preparation process showed that the AI-based technology reached 89% accuracy (surpassing the internal benchmark of 54%) and retrieved the right information 3.6 times faster.